top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 10 hours ago
  • 1 min read

07/04/2026










Climb Bio announced FDA Fast Track Designation for budoprutug for the treatment of pMN (Ref)


Climb Bio announced that the US FDA had granted Fast Track Designation to budoprutug (anti-CD19 mAb) for the treatment of primary membranous nephropathy (pMN)


  • Brudoprutug was being studied in Phase 2 patinets with pMN 


  • The company anticipated initial data from Phase 2 study in H2 2026




bottom of page